Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
J Clin Microbiol. 2012 Feb;50(2):312-7. doi: 10.1128/JCM.06002-11. Epub 2011 Dec 7.
Limited clinical information is available regarding community onset infections caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. A case-control study was performed to evaluate the epidemiology and risk factors of these types of infections. A case patient was defined as a person whose clinical sample yielded ESBL-producing E. coli. For each case patient, one control was randomly chosen from a group of outpatients from whom non-ESBL-producing E. coli had been isolated and for whom a clinical sample had been sent to the same laboratory for culturing during the following week. Of 108 cases of ESBL-producing E. coli, 56 (51.9%) were classified as health care associated (HCA). Univariate analysis showed male gender, HCA infection, severe underlying illness, and a prior receipt of antibiotics to be associated with ESBL-producing E. coli. In the multivariate analysis, HCA infection (odds ratio [OR], 3.18; 95% confidence interval [CI], 1.67 to 6.06; P < 0.001) and previous use of antibiotics (OR, 4.88; 95% CI, 2.08 to 11.48; P < 0.001) were found to be significantly associated with the ESBL group. In a multivariate analysis that included each antibiotic, previous use of fluoroquinolone (OR, 7.32; 95% CI, 1.58 to 34.01; P = 0.011) was significantly associated with ESBL-producing E. coli. Of 101 isolates in which ESBLs and their molecular relationships were studied, all isolates produced ESBLs from the CTX-M family (CTX-M-14, 40 isolates; CTX-M-15, 39 isolates; and other members of the CTX-M family, 22 isolates). In conclusion, this study confirms that ESBL-producing E. coli strains are a notable cause of community onset infections in predisposed patients. HCA infection and previous use of fluoroquinolone were significant factors associated with ESBL-producing E. coli in community onset infections.
有关产超广谱β-内酰胺酶(ESBL)大肠埃希菌引起的社区获得性感染的临床信息有限。进行了一项病例对照研究,以评估此类感染的流行病学和危险因素。病例患者定义为临床样本中分离出产 ESBL 大肠埃希菌的患者。对于每个病例患者,从同一家实验室在接下来一周内培养的、分离出非产 ESBL 大肠埃希菌且临床样本送检的门诊患者中随机选择 1 名对照。在 108 例产 ESBL 大肠埃希菌中,56 例(51.9%)归类为医源性感染(HCA)。单因素分析显示,男性、HCA 感染、严重基础疾病和既往使用抗生素与产 ESBL 大肠埃希菌有关。多因素分析显示,HCA 感染(比值比[OR],3.18;95%置信区间[CI],1.67 至 6.06;P<0.001)和既往使用抗生素(OR,4.88;95%CI,2.08 至 11.48;P<0.001)与 ESBL 组显著相关。在包括每种抗生素的多因素分析中,既往使用氟喹诺酮(OR,7.32;95%CI,1.58 至 34.01;P=0.011)与产 ESBL 大肠埃希菌显著相关。在研究 ESBL 及其分子关系的 101 株分离株中,所有分离株均产生 CTX-M 家族的 ESBL(CTX-M-14,40 株;CTX-M-15,39 株;以及 CTX-M 家族的其他成员,22 株)。总之,本研究证实产 ESBL 大肠埃希菌菌株是易感患者社区获得性感染的重要原因。HCA 感染和既往使用氟喹诺酮是社区获得性感染中产 ESBL 大肠埃希菌的显著相关因素。